The US FDA grants accelerated approval to cancer drugs to provide patients with faster access to potentially beneficial therapies, but the downside is that the effectiveness of these drugs is often unclear. A recent study published in Lancet Oncology found that many patients are willing to wait for greater certainty that a new drug provides a survival benefit. While patients value timely access to new drugs, they also prioritize evidence of overall survival benefits. The study suggests that accelerated approvals without mandating survival endpoint in confirmatory trials may not align with the preferences of many patients who prioritize certainty over speed of access.
Source link
Do Patients Prefer Access or Benefit?
